Pluristem’s PLX Cells Show A Statistically Significant Advantage In A Pre-Clinical Study In The Multiple Sclerosis Model

Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT) a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that a preclinical study utilizing the Company’s PLacental eXpanded (PLX) cells showed a statistically significant advantage in ameliorating functional deficiencies in a standard Multiple Sclerosis (MS) animal model.

More: continued here

Filed under: Multiple Sclerosis on April 17th, 2008